TWI251495B - Pharmaceutical composition without unpleasant taste - Google Patents
Pharmaceutical composition without unpleasant taste Download PDFInfo
- Publication number
- TWI251495B TWI251495B TW089104960A TW89104960A TWI251495B TW I251495 B TWI251495 B TW I251495B TW 089104960 A TW089104960 A TW 089104960A TW 89104960 A TW89104960 A TW 89104960A TW I251495 B TWI251495 B TW I251495B
- Authority
- TW
- Taiwan
- Prior art keywords
- hydrochloride
- group
- pharmaceutical composition
- unpleasant taste
- drug
- Prior art date
Links
- 235000019640 taste Nutrition 0.000 title claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 47
- 229940079593 drug Drugs 0.000 claims abstract description 45
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 239000008187 granular material Substances 0.000 claims description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 32
- 239000000843 powder Substances 0.000 claims description 30
- 238000005469 granulation Methods 0.000 claims description 27
- 230000003179 granulation Effects 0.000 claims description 27
- -1 fatty acid esters Chemical class 0.000 claims description 21
- 239000000126 substance Substances 0.000 claims description 20
- 239000007921 spray Substances 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 239000000194 fatty acid Substances 0.000 claims description 13
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 11
- 229930195729 fatty acid Natural products 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 230000001747 exhibiting effect Effects 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229960000278 theophylline Drugs 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 4
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 claims description 4
- 229960000520 diphenhydramine Drugs 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 229960003376 levofloxacin Drugs 0.000 claims description 4
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims description 4
- 229960002695 phenobarbital Drugs 0.000 claims description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 4
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical group FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 229960001699 ofloxacin Drugs 0.000 claims description 3
- 239000008183 oral pharmaceutical preparation Substances 0.000 claims description 3
- AKNNEGZIBPJZJG-MSOLQXFVSA-N (-)-noscapine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2[C@@H]1[C@@H]1C2=CC=C(OC)C(OC)=C2C(=O)O1 AKNNEGZIBPJZJG-MSOLQXFVSA-N 0.000 claims description 2
- QPXDKQBBJCTNOY-UHFFFAOYSA-N 1,10-phenanthrolin-10-ium;chloride Chemical compound Cl.C1=CN=C2C3=NC=CC=C3C=CC2=C1 QPXDKQBBJCTNOY-UHFFFAOYSA-N 0.000 claims description 2
- PTNZGHXUZDHMIQ-UHFFFAOYSA-N 4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2C(C)C(C(O)C3C(C(O)=C(C(N)=O)C(=O)C3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-UHFFFAOYSA-N 0.000 claims description 2
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 claims description 2
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 241000218671 Ephedra Species 0.000 claims description 2
- BALXUFOVQVENIU-GNAZCLTHSA-N Ephedrine hydrochloride Chemical compound Cl.CN[C@@H](C)[C@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-GNAZCLTHSA-N 0.000 claims description 2
- RHAXSHUQNIEUEY-UHFFFAOYSA-N Epirizole Chemical compound COC1=CC(C)=NN1C1=NC(C)=CC(OC)=N1 RHAXSHUQNIEUEY-UHFFFAOYSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 2
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- QTSXMEPZSHLZFF-UHFFFAOYSA-M Timepidium bromide Chemical compound [Br-].C1[N+](C)(C)CC(OC)CC1=C(C=1SC=CC=1)C1=CC=CS1 QTSXMEPZSHLZFF-UHFFFAOYSA-M 0.000 claims description 2
- 229960000723 ampicillin Drugs 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- 229960003589 arginine hydrochloride Drugs 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 2
- 229960004195 carvedilol Drugs 0.000 claims description 2
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 claims description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 2
- 229960005091 chloramphenicol Drugs 0.000 claims description 2
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims description 2
- 229960001380 cimetidine Drugs 0.000 claims description 2
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 2
- 229960002626 clarithromycin Drugs 0.000 claims description 2
- 229960001985 dextromethorphan Drugs 0.000 claims description 2
- 229960004082 doxycycline hydrochloride Drugs 0.000 claims description 2
- 229960002534 ephedrine hydrochloride Drugs 0.000 claims description 2
- 229960003276 erythromycin Drugs 0.000 claims description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 2
- 229960002001 ethionamide Drugs 0.000 claims description 2
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960001596 famotidine Drugs 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- ZUXNZUWOTSUBMN-UHFFFAOYSA-N hydralazine hydrochloride Chemical compound Cl.C1=CC=C2C(NN)=NN=CC2=C1 ZUXNZUWOTSUBMN-UHFFFAOYSA-N 0.000 claims description 2
- 229960005384 hydralazine hydrochloride Drugs 0.000 claims description 2
- MPGBPFMOOXKQRX-UHFFFAOYSA-N indenolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CC2 MPGBPFMOOXKQRX-UHFFFAOYSA-N 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 claims description 2
- 229960004503 metoclopramide Drugs 0.000 claims description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 2
- 229960004760 naphazoline hydrochloride Drugs 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 claims description 2
- 229960004872 nizatidine Drugs 0.000 claims description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
- 229960002895 phenylbutazone Drugs 0.000 claims description 2
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 claims description 2
- 229960000627 roxatidine acetate hydrochloride Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001544 sulfathiazole Drugs 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 229960001367 tartaric acid Drugs 0.000 claims description 2
- 229960004989 tetracycline hydrochloride Drugs 0.000 claims description 2
- 229960003737 timepidium bromide Drugs 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 claims 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 claims 1
- UOTMYNBWXDUBNX-UHFFFAOYSA-N 1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxyisoquinolin-2-ium;chloride Chemical compound Cl.C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 UOTMYNBWXDUBNX-UHFFFAOYSA-N 0.000 claims 1
- CIVCELMLGDGMKZ-UHFFFAOYSA-N 2,4-dichloro-6-methylpyridine-3-carboxylic acid Chemical compound CC1=CC(Cl)=C(C(O)=O)C(Cl)=N1 CIVCELMLGDGMKZ-UHFFFAOYSA-N 0.000 claims 1
- FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 claims 1
- UBDZFAGVPPMTIT-UHFFFAOYSA-N 2-aminoguanidine;hydron;chloride Chemical compound [Cl-].NC(N)=N[NH3+] UBDZFAGVPPMTIT-UHFFFAOYSA-N 0.000 claims 1
- 235000019737 Animal fat Nutrition 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 claims 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 claims 1
- 229920002581 Glucomannan Polymers 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims 1
- 241000282376 Panthera tigris Species 0.000 claims 1
- 241000972672 Phellodendron Species 0.000 claims 1
- 241000246044 Sophora flavescens Species 0.000 claims 1
- 241001113787 Strychnos Species 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 claims 1
- 230000008033 biological extinction Effects 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims 1
- 229960002079 calcium pantothenate Drugs 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- FBSMERQALIEGJT-UHFFFAOYSA-N chlorpromazine hydrochloride Chemical compound [H+].[Cl-].C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 FBSMERQALIEGJT-UHFFFAOYSA-N 0.000 claims 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 claims 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 claims 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 claims 1
- 229960000648 digitoxin Drugs 0.000 claims 1
- 229960005316 diltiazem hydrochloride Drugs 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 229960000525 diphenhydramine hydrochloride Drugs 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 229940046240 glucomannan Drugs 0.000 claims 1
- 239000010015 huanglian Substances 0.000 claims 1
- XZZXIYZZBJDEEP-UHFFFAOYSA-N imipramine hydrochloride Chemical compound [Cl-].C1CC2=CC=CC=C2N(CCC[NH+](C)C)C2=CC=CC=C21 XZZXIYZZBJDEEP-UHFFFAOYSA-N 0.000 claims 1
- 229960002102 imipramine hydrochloride Drugs 0.000 claims 1
- 229960005357 lysine acetate Drugs 0.000 claims 1
- 229960005337 lysine hydrochloride Drugs 0.000 claims 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 1
- 229960004708 noscapine Drugs 0.000 claims 1
- 229960003207 papaverine hydrochloride Drugs 0.000 claims 1
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 1
- PMZURENOXWZQFD-UHFFFAOYSA-L sodium sulphate Substances [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 1
- 235000011152 sodium sulphate Nutrition 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 235000019871 vegetable fat Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 19
- 230000000873 masking effect Effects 0.000 abstract description 14
- 239000000463 material Substances 0.000 abstract description 3
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- 230000009747 swallowing Effects 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 22
- 238000012360 testing method Methods 0.000 description 14
- 238000007922 dissolution test Methods 0.000 description 13
- 239000006185 dispersion Substances 0.000 description 11
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 11
- 238000004090 dissolution Methods 0.000 description 10
- 239000004372 Polyvinyl alcohol Substances 0.000 description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 description 7
- 238000002627 tracheal intubation Methods 0.000 description 7
- 108010011485 Aspartame Proteins 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 239000000605 aspartame Substances 0.000 description 6
- 235000010357 aspartame Nutrition 0.000 description 6
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 6
- 229960003438 aspartame Drugs 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 238000005507 spraying Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000001856 Ethyl cellulose Substances 0.000 description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 230000002079 cooperative effect Effects 0.000 description 5
- 235000019325 ethyl cellulose Nutrition 0.000 description 5
- 229920001249 ethyl cellulose Polymers 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 229920003169 water-soluble polymer Polymers 0.000 description 4
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 229950008882 polysorbate Drugs 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 229920003176 water-insoluble polymer Polymers 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- KQBVVLOYXDVATK-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indole Chemical compound C1CCCC2=C1C=CN2 KQBVVLOYXDVATK-UHFFFAOYSA-N 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- 241001674044 Blattodea Species 0.000 description 2
- 239000005944 Chlorpyrifos Substances 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 244000294411 Mirabilis expansa Species 0.000 description 2
- 235000015429 Mirabilis expansa Nutrition 0.000 description 2
- 241001079007 Phellodendron chinense Species 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- SBPBAQFWLVIOKP-UHFFFAOYSA-N chlorpyrifos Chemical compound CCOP(=S)(OCC)OC1=NC(Cl)=C(Cl)C=C1Cl SBPBAQFWLVIOKP-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229940075507 glyceryl monostearate Drugs 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000007909 melt granulation Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000013536 miso Nutrition 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- CXZOCEZMGWOOFD-UHFFFAOYSA-N phenanthren-1-amine Chemical compound C1=CC2=CC=CC=C2C2=C1C(N)=CC=C2 CXZOCEZMGWOOFD-UHFFFAOYSA-N 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- AHJGUEMIZPMAMR-WZTVWXICSA-N 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxoquinoline-3-carboxylic acid;(2r,3r,4r,5s)-6-(methylamino)hexane-1,2,3,4,5-pentol Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=C(F)C(N)=NC(N2C3=C(Cl)C(N4CC(O)C4)=C(F)C=C3C(=O)C(C(O)=O)=C2)=C1F AHJGUEMIZPMAMR-WZTVWXICSA-N 0.000 description 1
- IEPMBYOIQGCVHO-UHFFFAOYSA-N 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydron;chloride Chemical compound Cl.C1CNC(C)CN1C(C(=C1C)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 IEPMBYOIQGCVHO-UHFFFAOYSA-N 0.000 description 1
- JHFAEUICJHBVHB-UHFFFAOYSA-N 1h-indol-2-ol Chemical compound C1=CC=C2NC(O)=CC2=C1 JHFAEUICJHBVHB-UHFFFAOYSA-N 0.000 description 1
- WWJBDSBGLBEFSH-UHFFFAOYSA-N 2-(4-methoxyphenyl)azepane Chemical compound C1=CC(OC)=CC=C1C1NCCCCC1 WWJBDSBGLBEFSH-UHFFFAOYSA-N 0.000 description 1
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- AKUVRZKNLXYTJX-UHFFFAOYSA-N 3-benzylazetidine Chemical compound C=1C=CC=CC=1CC1CNC1 AKUVRZKNLXYTJX-UHFFFAOYSA-N 0.000 description 1
- MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 description 1
- LEILBPMISZFZQK-GFCCVEGCSA-N 5-amino-7-[(7s)-7-azaniumyl-5-azaspiro[2.4]heptan-5-yl]-1-cyclopropyl-6-fluoro-8-methyl-4-oxoquinoline-3-carboxylate Chemical compound C12([C@H](N)CN(C1)C1=C(C3=C(C(C(C(O)=O)=CN3C3CC3)=O)C(N)=C1F)C)CC2 LEILBPMISZFZQK-GFCCVEGCSA-N 0.000 description 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- UPCHGBDAUCFDMW-UHFFFAOYSA-N 6-fluoro-1-(5-fluoropyridin-2-yl)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydron;chloride Chemical compound Cl.C1CN(C)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=N1 UPCHGBDAUCFDMW-UHFFFAOYSA-N 0.000 description 1
- BMACYHMTJHBPOX-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid;hydron;chloride Chemical compound Cl.C1C(N)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1Cl BMACYHMTJHBPOX-UHFFFAOYSA-N 0.000 description 1
- MPORYQCGWFQFLA-ONPDANIMSA-N 7-[(7s)-7-amino-5-azaspiro[2.4]heptan-5-yl]-8-chloro-6-fluoro-1-[(1r,2s)-2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;trihydrate Chemical compound O.O.O.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1.C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 MPORYQCGWFQFLA-ONPDANIMSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- KTNROWWHOBZQGK-UHFFFAOYSA-N Etilefrine hydrochloride (TN) Chemical compound [Cl-].CC[NH2+]CC(O)C1=CC=CC(O)=C1 KTNROWWHOBZQGK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 240000001090 Papaver somniferum Species 0.000 description 1
- 235000008753 Papaver somniferum Nutrition 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- PWNMXPDKBYZCOO-UHFFFAOYSA-N Prulifloxacin Chemical compound C1=C2N3C(C)SC3=C(C(O)=O)C(=O)C2=CC(F)=C1N(CC1)CCN1CC=1OC(=O)OC=1C PWNMXPDKBYZCOO-UHFFFAOYSA-N 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 206010061549 Sensation of foreign body Diseases 0.000 description 1
- DPOPAJRDYZGTIR-UHFFFAOYSA-N Tetrazine Chemical compound C1=CN=NN=N1 DPOPAJRDYZGTIR-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- 229930101531 artemisinin Natural products 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005199 aryl carbonyloxy group Chemical group 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- FHRSHSOEWXUORL-HDJSIYSDSA-N cetraxate Chemical compound C1C[C@@H](C[NH3+])CC[C@@H]1C(=O)OC1=CC=C(CCC([O-])=O)C=C1 FHRSHSOEWXUORL-HDJSIYSDSA-N 0.000 description 1
- 229950009533 cetraxate Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- BLUAFEHZUWYNDE-XRNKLDBLSA-N chembl77 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4C31[C@@H]2OC(=O)[C@@H]4C BLUAFEHZUWYNDE-XRNKLDBLSA-N 0.000 description 1
- 125000004803 chlorobenzyl group Chemical group 0.000 description 1
- 229960001657 chlorpromazine hydrochloride Drugs 0.000 description 1
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 1
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000005201 cycloalkylcarbonyloxy group Chemical group 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000006612 decyloxy group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229930004069 diterpene Natural products 0.000 description 1
- 150000004141 diterpene derivatives Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960005172 etilefrine hydrochloride Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960003306 fleroxacin Drugs 0.000 description 1
- XBJBPGROQZJDOJ-UHFFFAOYSA-N fleroxacin Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN(CCF)C2=C1F XBJBPGROQZJDOJ-UHFFFAOYSA-N 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960003984 grepafloxacin hydrochloride Drugs 0.000 description 1
- PPZMYIBUHIPZOS-UHFFFAOYSA-N histamine dihydrochloride Chemical compound Cl.Cl.NCCC1=CN=CN1 PPZMYIBUHIPZOS-UHFFFAOYSA-N 0.000 description 1
- 229960000645 histamine hydrochloride Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229950008838 indenolol Drugs 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N isomenthone Natural products CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 239000009313 kushen Substances 0.000 description 1
- 229960003814 lomefloxacin hydrochloride Drugs 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229950002475 mesilate Drugs 0.000 description 1
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 description 1
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 229960002625 pazufloxacin Drugs 0.000 description 1
- NSAXZQMIPDNMFQ-UHFFFAOYSA-N pentane;hydrochloride Chemical compound Cl.CCCCC NSAXZQMIPDNMFQ-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960004604 propranolol hydrochloride Drugs 0.000 description 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 229960001224 prulifloxacin Drugs 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 229960005206 pyrazinamide Drugs 0.000 description 1
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229960003177 sitafloxacin Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000019654 spicy taste Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- RLUJQBLWUQZMDG-UHFFFAOYSA-N toluene;hydrochloride Chemical compound Cl.CC1=CC=CC=C1 RLUJQBLWUQZMDG-UHFFFAOYSA-N 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Glanulating (AREA)
Description
1251495 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(1 ) 技術範嗜 本發明係關於遮蔽藥物之不快味道且服用感良好之粒狀 醫藥組合物,以及用其製成之製劑。 技術背景 經口投與製劑若具有不快味道,則服用者之順從性降低 而常得不到期待之治療效果。 有關細粒劑做爲不快味道之遮蔽法者,已知有使用水不 溶性高分子之噴霧包覆法及藉由微膠囊化或添加甘味劑之 方法等。關於使用水不溶性高分子之噴霧包覆法,例如特 開昭62-30709號公報揭示一種用乙基纖維素包覆含有藥物 之核而成之持續性製劑,並記載藉著改變乙基纖維素膜之 厚度可凋節藥物之釋出速度。然而此種持續性製劑之技 術,非爲用於製備兼具不快味遮蔽性之速放性製劑之技 術。再者’使用水不溶性高分子施行包覆者,含在口中時 有異物感且咬在齒中時會痛等,而有服用性之問題。另一 方面,藉由微膠囊化之方法,除了使用有機溶劑等之製法 相當複雜外,更因產率低而有製造成本高等之缺點。至於 藉由添加甘味劑之方法,則對於不快味遒強烈之藥物遮蔽 效果不足。 又在特開平7-242568號公報中,揭示將熔點45〜9〇。〇之 疏水性物質及界面活性劑加溫熔解及將呈現不快風味之藥 物及導水劑溶解或懸浮後,將該液噴霧造粒而得到粒狀製 劑。添加界面活性劑及導水劑之目的係爲使藥物之溶出性 加速,其在組合物中分別含有5〜35%。從安全性之觀點言 本紙張尺度適用中國國家標準(CNS)A4規格(210 297公釐) (請先閱讀背面之注意事項再填寫本頁) --------訂---------· 1251495 經濟部智慧財產局員工消費合作社印製 A7 五、發明說明(2 之界面’舌性劑以使用少量爲較佳。又若考慮噴霧造粒後 、製♦力 雖然噴務造粒中之添加劑以使用少量爲較 佳仁是在噴霧造粒後之製粒加工中,以能夠使用多量其 他的添加劑爲較佳,因此界面活性劑及導水劑若沒有使用 限制將較爲有利。特開平7-267850號公報中揭示,藉由將 種或數種具有不快味道之藥物、一種或數種水溶性高分 子及種或數種蟠狀物質混合,加熱,然後將溶解後之虫嚴 狀物質與藥物及水溶性高分子共同造粒而得到醫藥組| 物、加水性咼分子之目的,與上述同樣係爲使藥物之 溶出性加速,其在該組合物中之配合量爲5〜6〇%。然而, 基於上述同樣之理由,以不使用或只使用少量水溶性高分 子爲較佳。 再者,關於固形粒狀物(特別爲散劑)令人滿意之品質, 除了具有上述不快味道之遮蔽性外,例如尚有適於經插管 投與。經插管投與主要爲針對無法吞嚥製劑之服用者所實 施I投與万法,將散劑在水中分散後移入注射器,將其從 服用者之鼻或腹部經由被插入消化道之管子注入而投與之 方法。由於分散劑多於用時調製,因此散劑在短時間能均 勻分散且在注射器及管子内不堵塞爲主要要求。然而,用 甲基丙晞酸共聚物等pH依存性高分子包覆之散劑,由於 會在精製水及葡萄糖等非電解質液中凝集,在注射器及管 子内會發生堵塞,而不適合經插管投與。又使用乳糖等糖 類做爲賦形劑之散劑,由於也會在注射器及管子内^成堵 塞,所以不適合經插管投與。 私紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐 --------tr--------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1251495 A7 _B7_ 五、發明說明(3 ) 因此,本發明之目的,乃在提供一種對於藥物之不快味 道具有優異遮蔽性,服用感良好,且亦能經由插管投與之 粒狀醫藥組合物,及使用其製成之製劑。 發明之揭示 基於上述,本發明人等針對配合有呈現不快味道之藥物 之粒狀物之製造及其性能加以種種檢討,意外地發現若將 呈現不快味道之藥物與蠟狀物質及糖醇配合,可得到不快 味道之遮蔽效果優異且服用感良好之醫藥製劑,因而完成 本發明。再者,發現該醫藥製劑也可以經由插管投與。 亦即,本發明係提供含有呈現不快味道之藥物、蠟狀物 質及糖醇之粒狀醫藥組合物、其製造方法及含有此粒狀醫 藥組合物之口服醫藥製劑。 實施本發明之最佳形態 在本發明中,所謂「不快味道」係指服用者將藥物含在 口中所感覺到之苦味、澀味、辣味、刺激味以及臭味。 在本發明中,作爲「呈現不快味道之藥物」者,只要呈 現上述之不快味道而可做爲醫藥使用之藥物皆可,而沒有 其他特別限制。例如可爲選自下列者之藥物:遠德拉賽特 (cetraxate)鹽酸鹽、埃卡巴皮多、涅飛拉血丹、g太胺芊青黴 素(talanpicillin)鹽酸鹽、印得諾樂爾(indenolol)鹽酸鹽、肼 酉太嗪(hydralazine)鹽酸鹽、氯丙喚(chlorpromazine)鹽酸鹽、 續胺p塞峻(thiazamide)鹽酸鹽、氯化小蘗驗(berberine chloride)、毛地黃毒嘗(digitoxin)、安乃近(sulpyrin)、阿瑟 粒斯汀鹽酸鹽、乙苯福林(etilefrine)鹽酸鹽、硫氮萆酮 -6- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ------:--------------訂---------線· (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1251495 A7 B7 五、發明說明(4 ) (diltiazem)鹽酸鹽、萘心安(propranolol)鹽酸鹽、氯徽素 (chloramphenicol)、胺基菲林(aminophyllin)、紅黴素、澄清 黴素(clarithromycin)、苯巴比妥(phenobarbital)、泛酸 #5、印 得羅莎淀鹽酸鹽、胺基胍(aminoguanidine)鹽酸鹽、比菲美 藍鹽酸鹽、7β- [ 2- ( 2-胺基遠峻-4-基)-2-(Z)-無亞胺基乙酉盛 胺]·3-Ν,Ν-二甲胺甲醯氧甲基·3·瑟菲姆(cephem)羧酸1-(異 丙氧羰氧基)乙酯鹽酸鹽、(E)-3- ( 2-甲氧基-3,6-二甲基-1,4-苯酿-5-基)-2- [ 5- ( 3- p比淀基)戊基]-2-丙稀酸、胺基菲 林(aminophyllin)、茶驗(theophylline)、苯海拉明 (diphenhydramine)、滅吐靈(metoclopramide)、苯基保泰松 (phenylbutazone)、苯巴比妥(phenobarbital)、胺爷青徽素 (ampicillin)、西美替淀(cimetidine)、法摩替淀(famotidine)、 尼札替淀(nizatidine)、乙酸胺基苯酴(acetoaminophen)、野 匹立柔(epirizol)、ρ比嗅S盛胺(pyrazinamide)、咖#因、乙硫 異煙胺(ethionamide)、卡威迪柔(carvedilol)、糖硝晞二胺 (ranitidine)鹽酸鹽、乙酸羅沙淀醋(roxatidine acetate)鹽酸 鹽、丙咪嗅(imipramine)鹽酸鹽、麻黃驗(ephedrine)鹽酸 鹽、苯海拉明(diphenhydramine)鹽酸鹽、斗内戊基鹽酸鹽、 四環素鹽酸鹽、去氧土黴素(doxycycline)鹽酸鹽、莕峻琳 (naphazoline)鹽酸鹽、諾司卡品(noscapine)鹽酸鹽、罌粟驗 (papaverine)鹽酸鹽、氫漠酸美沙芬(dextromethorphan)、溪 化遠甲p比淀(timepidium bromide)、馬來酸氯苯p比胺 (chlorpheniramine maleate)、 酒石酸阿立眉馬淀、皮爾丁卡 耐德鹽酸鹽、N_甲基藍营胺(scopolamine)甲基硫酸鹽、馬 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ------:--------------訂---------線 (請先閱讀背面之注意事項再填寫本頁) R2c
COOH 1251495 A7 ___B7 五、發明說明(5 ) 來酸西注帕紀德、精胺酸鹽酸鹽、組胺酸鹽酸鹽、離胺酸 鹽酸鹽、離胺酸醋酸鹽、恩格沙克、黃柏、黃蓮、馬錢 子、」麻黃、吐根、莫菪根、顚蘇、苦參等之生藥或者此等 生藥之萃取物、以下述通式(1)〜(4)所表示之吡啶酮羧酸化 合物或其鹽類:
,COOH R】a ( 1 ) (2)
(式中:Rla、Rlb及Ri。分別獨立表示可具有取代基之 q-C6直鏈狀或分枝狀烷基、可具有取代基之CyQ之環烷 基、可具有取代基之芳基或可具有取代基之雜芳基; R 、R 、R2e及R2d分別獨立表示氫原子、可具有取代 基之CVC6直鏈狀或分枝狀烷基、或胺基; & 、R 、R及R3d分別獨立表示氫原子或鹵素原子; R4a或R4c表示氫原子、鹵素原子、可具有取代基之Cl_c6 直鏈狀或分枝狀烷基或可具有取代基之Cl_C6直鏈狀或分 枝狀烷氧基; R5d表示氫原子或可具有取代基之Cl-c6直鏈狀或分枝狀 本紙張尺度適用中關家標準(CNS)A4規格(21G χ 297公爱) ------Γ.--一-----------—訂---------線· (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1251495
五、發明說明(6 基;以及 Y及γ分別獨立表示含氮基),以及 {請先閱讀背面之注音?事項再填寫本頁) 以下述通式⑺表示之4,5,6,7-四氫嘧吩幷[3,2-c]吡啶類 或其鹽類: R^CH(R2).R3 (5) [式中: R1表示之苯基,其可具有丨〜3個從Ci_C4烷基、自素原 子、氟代eve:4烷基、Ci_C4烷氧基、氟代Ci_C4烷氧基、 胺基及硝基所形成組群中選出之取代基; R表不氫原子、羧基、Ci-C0烷氧羰基、或者可被鹵素 原子、羥基、cKC6烷氧基或氰基取代之Ci_C7脂肪族醯 基; R3表示可被下列基取代之4,5,6,7 _四氫嘧吩幷[3,2_c]吡 啶-5-基:羥基、Cl_C4烷氧基、被^―匕烷氧基或Ci_G烷 羰氧基取代之CrC4烷氧基、C7_Ci4芳烷氧基、Ci-Ci8烷羰 氧基、CVC7環烷羰氧基、C6_CiG芳羰氧基、Ci-C4烷氧羰 氧基或Ct-Cm芳烷氧羰氧基]。 經濟部智慧財產局員工消費合作社印製 前述通式(1)〜(4)中所表示之吡啶酮羧酸化合物及其鹽 類,如特開昭53-141286號公報、特開昭55_31〇42號公 報、特開昭57-46986號公報、特開昭57_77683號公報、特 開昭60-36482號公報、特開昭60·64979號公報、特開昭 60-228479號公報、特開昭62-252772號公報、特開昭62_ 252790號公報、特開昭62-277302號公報、特開平1β 230558號公報、特開平1-258666號公報、特開平^294680 -9- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) "'' 1251495 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(7 ) 號公報、特開平2-28178號公報、特開平2-124873號公 報、特開平2-231475號公報、特開平5-271229號公報、特 開平 7-309864 號公報、特開平 8-41050 號公報、 WO91/02526 號公報、W094/14794 號公報、W094/15933 號 公報、W095/5373 號公報、W096/37475 號公報、 WO96/39407 號公報、WO97/29102 號公報、WO97/19072 號 公報、W097/40037號公報、WO98/02431 號公報、 WO98/13370 號公報、W098/18783 號公報、W098/24781 號 公報、W098/52939號公報、W098/54169號公報及 W098/58923號公報中所記載,此等公開公報中也記載其製 造方法。再者,通式(5)中所表示之化合物及其鹽類,可 根據特開昭50-46688號公報、特開昭58-10583號公報、特 開昭59-27895號公報、特開平6-41139號公報中所記載之 方法製造。 上述通式(1)〜(5)中所表示之化合物,若有不對稱碳而存 在光學異構物或非對映異構物,則無論爲此等異構物之純 粹形態,或此等異構物之任意混合物、消旋體等均被包含 在本發明之中。再者,上述通式(1)〜(5)中所表示之化合物 或其鹽類若存在水合物或溶媒合物,則其也均被包含在本 發明之中。 在本發明中,呈現不快味道之藥物杳,從遮蔽效果之觀 點而言,以在蠟狀物質中具有難溶性者爲較佳,又以水溶 性而在躐狀物質中具有難溶性者爲更佳。 再者’上述通式(1)〜(4)中所表示之化合物或其鹽類之車交 佳實例,如下列化合物或其鹽類。 10- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ------·--------------訂---------線 (請先閱讀背面之注意事項再填寫本頁) 1251495
ο ο
OH (歐氟羅沙辛)
、0H (左旋敷羅沙辛)
Ciprofloxacin hydrochloride(環丙氟羅沙辛鹽酸鹽)
(請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製
‘0H
Si tafloxacin(西塔氟羅沙♦·) (投蘇氟羅沙辛甲苯續酸鹽) 0
Moxifloxacin hydrochloride(莫西It羅沙辛鹽酸鹽) -11 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1251495 A7 B7 五、發明說明(9 HN、
、0H
Me,
X02H
Enoxacin(安諾沙辛) HN CS-940 HC^ 0 0
、0H Fleroxacin (氟來羅沙辛)
C02H (請先閱讀背面之注音?事展再填寫本頁) 0 0
S0H 經濟部智慧財產局員工消費合作社印製
Me 〇
Lomefloxacin hydrochloride (樓美氟羅沙辛鹽酸鹽) NH2 〇
CH3SO3H HSR-903
Grepafloxacin hydrochloride (才各來帕氣羅沙辛鹽酸鹽)
C02H
Pazuf loxacin 12- (帕茲象羅沙辛) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1251495 A7 B7 五、發明說明(10
co2h CH3SO3H Pazafloxacin mesilate (帕住氟羅沙辛甲續酸鹽)
Prulifloxacin(普里氟羅沙辛)
η2ν
0
C02H HC£ A-99058.L (請先閱讀背面之注意事項再填寫本頁)
Trovafloxacin mesilate (特羅法氟羅沙辛甲橫酸鹽)
Clinafloxacin hydrochloride(克里納氟羅沙+鹽酸鹽) H2N*
(艾挪諾氟羅沙辛) 經濟部智慧財產局員工消費合作社印製
(阿拉特洛氟羅沙辛甲續酸鹽) -13- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1251495 A7 B7 五、發明說明( 11
Me
(伊魯羅沙辛)丨
Fandofloxacin hydrochloride(芬朵氟羅沙辛鹽酸鹽)
co2h (請先閱讀背面之注意事項再填寫本頁)
co2h
nh2 SS-734 經濟部智慧財產局員工消費合作社印製
C02H -14- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1251495 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(12 )
WQ-3034 再者,在上述通式(5)所表示之化合物或其鹽中,較佳 之例子可被列舉者如下: 2-經基-5- ( α-環丙談基-2_氯爷基)-4,5,6,7-四氮p塞吩并 [3,2-c]吡啶, 2-無基-5- ( ex-丙酿基-2-氣卞基)-4,5,6,7-四鼠p塞吩并[3,2-c] 吡啶, 2-羥基-5- ( α-環丙羰基-2-氟苄基)-4,5,6,7-四氫嘧吩幷 [3,2-c] p比淀, 2-乙酿氧基-5· ( (X•環丙談基-2-氣卞基)-4,5,6,7-四鼠ρ塞吩 幷[3,2-c]吡啶, 2 -丙醯氧基-5- ( α-環丙羰基-2-氟芊基)-4,5,6,7-四氫嘧吩 幷[3,2-c]吡啶, 2- 丁醯氧基-5- ( α-環丙羰基-2-氟芊基)-4,5,6,7_四氫嘧吩 幷[3,2-c]吡啶, 2-特戊醯氧基-5- ( α-環丙羰基-2-氟芊基)-4,5,6,7-四氫嘧 吩并[3,2-c] p比淀, 2-戊酿氧基-5- ( oc_環丙談基-2·氣卞基)-4,5,6,7-四鼠p塞吩 -15- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -------i--------------訂----------線 (請先閱讀背面之注音2事展再填寫本頁) 1251495 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(I3 ) 弁[3,2-c]吡啶, 2-己醯氧基-5- ( α-環丙羰基-2 -氟苄基)-4,5,6,7-四氫嘧吩 幷[3,2-c] p比淀, 2-第三丁氧羰氧基_5_ ( α•環丙羰基-2-氟芊基)_ 4,5,6,7_四 氫嘍吩幷[3,2-c]吡啶, 2_特戊醯氧基甲氧基-5- ( α-環丙羰基-2-氟苄基)-4,5,6,7-四氫嘍吩幷[3,2-c]吡啶, 5_ ( α-環丙羰基-2-氟芊基)-2-氧基-2,4,5,6,7,7a-六氫嘧吩 弁[3,2-c]峨淀, 5- ( α·丙醯基-2-氟苄基)-2-氧基-2,4,5,6,7,7a-六氫嘧吩幷 [3,2-c]p比淀, 5- ( α-環丙羰基-2-氟苄基)-2•氧基-2,4,5,6,7,7a-六氫嘧吩 幷[3,2-c] ρ比淀, 2_乙酿氧基-5_ ( α-環丙羰基_2_氯苄基)-4,5,6,7-四氫遠吩 幷[3,2-c] ρ比淀, 2_護基_5- ( α_2-氟環丙羰基_2_氟苄基)-4,5,6,7-四氫嘧吩 幷[3,2-c] p比淀, 5- (α-2-氟環丙羰基_2_氟苄基卜2_氧基_2,4,5,6,7,7a_六氫 p塞吩幷[3,2-c] p比淀, 2-乙酸氧基( α_2_氟環丙羰基_2_氟苄基)_4,5,6,7_四氫 噻吩幷[3,2-c]吡啶, 5_ ( α-甲氧羰基-2·氯苄基)_2_氧基_2,4,5,6,7,7a-六氫嘍吩 并[3,2_c] ρ比淀, 2-乙醯氧基( α-甲氧羰基-2-氯芊基)-4,5,6,7-四氫嘧吩 - 16 - 本、、氏浪/又週用甲國國豕標準(cns)A4規格(21〇 X 297公釐) --------------------訂---------線"4^" (請先閱讀背面之注意事項再填寫本頁) 1251495
幷[3,2-c] p比淀, 五、發明說明(I4 ) 經濟部智慧財產局員工消費合作社印製 5_ ( α-甲氧羰基-2-氟苄基)·2_氧基-2,4,5,6,7,7a-六氫嘍吩 幷[3,2-c]^ 咬, 2-乙醯氧基-5- ( α-甲氧羰基·2_氟芊基)_4,5,6,7-四氫嘍吩 幷[3,2_c] p比淀, 5_ ( 2-氯苄基)-4,5,6,7_四氫嘧吩幷[3,2-c]吡啶(一般名爲 氯苄嘧啶(ticlopidine),可以做成鹽酸氯苄噻啶), 5- ( α-甲氧羧基-2-氯苄基)·4,5,6,7-四氫p塞吩幷[3,2_c]吡 呢(一般名爲氯啶格來爾(chlopidogrel),可做成氯啶格來爾 硫酸鹽), 5_ ( α_甲氧羰基-2·氟苄基)-4,5,6,7-四氫嘧吩幷[3,2_c]峨 咱:, 5- ( 環丙羰基-2·氯苄基)-4,5,6,7·四氫噻吩幷[3,2_c] 口比 淀, 5- ( α-環丙羰基-2-氟爷基)-4,5,6,7-四氫遠吩幷[3,2-c] p比 淀, 5-(α_丙酸基-2-氯爷基)_4,5,6,7·四氮ρ塞吩弁[3,2-c] p比 淀,及 5_ ( α_丙醯基_2_氟苄基)-4,5,6,7-四氫噻吩并[3,2-c]吡唉 以及其鹽。 在本發明中,呈現不快味道之藥物中以歐氟羅沙辛 (ofloxacin)、左旋氟羅沙辛(levofloxcin)、息塔氟羅沙辛 (citafloxacin)水合物、p塞德拉賽特(cetraxate)鹽酸鹽、淫飛 拉血丹、環皮症(cyclopidin)鹽酸鹽及氯皮都克菜爾 -17- -------U--------------訂---------線 (請先閱讀背面之注音?事項再填寫本頁} 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1251495
經濟部智慧財產局員工消費合作社印製 五、發明說明(I5 ) (chlopid〇grel)硫酸鹽爲較佳。 本發明中之躐狀物質(具體而言,熔點爲4〇〜15〇 t )例 如爲油脂如硬化蓖麻油、硬化大豆油、硬化菜種油、硬化 棉實油等之各種硬化油,巴西棕櫚蠟、白蠟、牛脂等植物 性及動物性油脂,醇類及多元醇如硬脂醇、鯨蠟醇等高級 醇,聚乙二醇4000、聚乙二醇60〇〇等聚乙二醇,脂肪酸 及其衍生物如硬脂酸、棕搁酸等高級脂肪酸,單脂肪酸甘 油、二爿曰肪·酸甘油酯等脂肪酸甘油酯類及蔗糖脂膀酸酯 續’或者其中2種以上之混合物等。其中,以硬化油、脂 肪酸、脂肪酸衍生物爲較佳,又以硬化油、高級脂肪酸、 脂肪酸醋類爲更佳,而以硬化油、單脂肪酸甘油酯、三脂 肪酸甘油酯、硬脂酸等爲特佳。再者,從藥物不快味道之 遮蔽效果而言,以蠟狀物質之熔點比藥物之熔點低者爲較 佳。 本發明中之糖醇以溶解熱低者爲較佳,例如原藻醇、木 糖醇、山梨醇、麥芽糖醇或其等2種以上之混合物爲較 佳。彳疋服用感之觀點而言,以溶解熱爲_3〇卡/公克以下之 糖醇爲較佳,而以原藻醇、木糖醇爲特佳。 本發明中呈現不快味道之藥物與躐狀物質之重量比,從 不快味道之遮蔽效果及溶出性平衡之觀點而言,以 1 : 1〜1 : 5之範圍爲較佳,而以1 : 2〜1 ·· 3之範圍爲更佳。更 且,糖醇之配合量,從不快味道之遮蔽效果、溶出性及服 用感之觀點而言,以粒狀組合物中之10重量%以上爲較 佳’以10〜99.9重置%爲更佳,而以20〜80重量%又更佳, -18 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ------^--------------訂---------線 (請先閱讀背面之注意事項再填寫本頁) 1251495
經濟部智慧財產局員工消費合作社印製 五、發明說明(I6 ) 以3〇〜70重量%爲特佳。 本發明之粒狀醫藥組合物,係藉著將蠟狀物質加溫熔解 以及使呈現不快味道之藥物分散或溶解後,用該分散液或 溶液進行第一次造粒,然後將得到之造粒物與糖醇進行混 合或第二次造粒而製造。 此處,第一次造粒之方法,可有噴霧造粒、熔融造粒及 將分散液或溶液冷卻固化後粉碎等,但以噴霧造粒爲較 佳。其中,又以噴霧冷卻法、噴霧乾燥法(由於容易得^ 具有較小粒徑之微粒子,使造粒物在舌上沒有粗糙等異物 感覺)爲較佳。粒子徑以50〜200微米爲較佳,而以8〇〜12〇 微未爲特佳。 在採用噴霧造粒做爲第一次造粒法之場合,爲了減輕噴 霧冷卻時所用製造機内壁之附著現象,也可添加少量之界 面活性劑。界面活性劑之添加量爲第一次造粒物之〇 5〜5 重量%,而以約1〜4重量%較佳。 關於用第一次造粒得到之造粒物與糖醇進行第二次造粒 之方法,例如有使用護丙基纖維素、經丙甲基纖維素、聚 乙烯基吡咯啶酮等黏合劑溶液之濕式流動層造粒法,以及 用聚乙二醇、單硬脂酸甘油酯等低熔點物質做爲粘合劑之 溶融造粒法等。 本發明之粒狀醫藥組合物,以將第一次造粒得到之粒狀 物與糖醇進行第二次造粒而得者爲較佳。亦即,由於第二 次造粒所使用之糖醇在口中被唾液於10秒鐘左右溶解, 所以只殘留第一次造粒得到之有藥物分散之蠟狀物質粒 _______ -19· + @ @ii^s)A4 規格⑽ X 297 公釐) "~^ —.—j--------------訂---------線 (請先閱讀背面之注意事項再填寫本頁) 1251495
五、發明說明(Π 可照原樣或者與其他添加劑 乾糖漿劑、錠劑、膠囊劑等 顆粒劑、乾糖漿劑爲較佳。 可有聚乙缔基P比P各淀酮、聚
子,既然蠟狀物質粒子爲I ϊ 、丄A ^ 馬掀小又球體,所以不會感到里物 感。再者,藥物係被均匄八鬼—W, /、物 勻刀政在虫鼠狀物質中,粒子形 時,由於在口中溶解極少, 7吸 所以使樂物之不快味遒得到 好之遮蔽。再者,由於糖醇(尤其是原藻醇、木糖醇)含在 口:時具有甜味及清涼感,所以可對藥物之不快味道予以 遮敝。输狀物質粒子被呑端接 ^ 奋撕後,於消化管中將藥物釋出, 釋出之藥物被身體吸收。 本發明之粒狀醫藥組合物 配合’而做成散劑、顆粒劑 口服醫藥製劑。其中以散劑 此處所使用之其他添加劑 乙晞醉、Μ基纖㈣、㈣甲基纖維素、甲基纖維素 聚乙二醇、單硬脂酸甘油醋等枯合劑,阿斯巴甜、糖精 鈉、糖精、索馬精、斯替維亞等甘味劑,dl_薄荷醇、^ 薄荷醇等香料,輕質無水矽酸、矽酸鋁酸鎂、滑石、合成 石夕酸铭、乙基纖維素等流動化劑,交聯m纖維素:、 澱粉葡糖酸鈉、低置換度羥丙基纖維素等崩散劑,檸檬酸 鈉、碳酸氫鈉等pH調節劑等。,添加劑雖可含有水溶性 高分子,但在本發明中以少量(如製劑之〇1〜5重量%)添 加爲較佳,而以1〜4重量%爲特佳。 實例 以下’舉出實例進一步説明本發明,但本發明並不爲其 所限制。 實例1 -20- 本紙張尺度適用中國國家標準(CNS)A4規格(210>< 297公釐) --------訂---------^ f請先閱讀背面之注音W事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 A7
1251495 五、發明說明(l8 ) 使單硬脂酸甘油酯200重量份在約9〇 τ熔解,並將左旋 氟羅沙辛(leV〇floxcin)100重量份均勻分散於其中。將此分 散液使用噴霧乾燥器噴霧冷卻,得到微小造粒物。在此造 粒物300重里份中加入原藻醇63〇重量份,使用流動層造 粒機此合後,以相當於聚乙烯醇1〇重量份之%聚乙 烯醇水溶液噴霧,進行流動造粒。噴霧終了後,繼續在流 動層造粒機内進行乾燥,得到造粒物。將此造粒物使用3〇 號篩網(孔目500微米)篩過,得到散劑。 實例2 使早硬爿曰敗甘油酯197重量份在約90 °C溶解,在其中混 合入聚氧伸乙基(20)山梨糖醇酐單油酸酯(聚山梨酸酯8〇) 3重量份。然後於此混合液中,將左旋氟羅沙辛 (levofloxcin) 1〇〇重量份均勻分散。將此分散液使用噴霧乾 燥器噴霧冷卻,得到微小造粒物。在此造粒物3〇〇重量份 中加入原藻醇630重量份,使用流動層造粒機混合後,以 相當於聚乙烯醇20重量份之10W/V%聚乙烯醇水溶液噴 霧,進行流動造粒。噴霧終了後,繼續在流動層造粒機内 進行乾燥,得到造粒物。將此造粒物使用30號篩網(孔目 500微米)篩過,得到散劑。 以與實例1及2同樣之方法,分別使用歐氟羅沙辛 (ofloxacin)、息塔氟羅沙辛(citafloxacin)水合物、p塞德拉赛 特(cetraxate)鹽酸鹽及涅飛拉血丹製造散劑。 試驗例1(不快味道遮蔽性評價:官能試驗1) 用實例1得到之散劑940毫克及實例2得到之散劑950 -21· 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ^ --------^---------^—^1 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1251495 A7 B7 五、發明說明(l9 ) (請先閱讀背面之注意事項再填寫本頁) 耄克進行官能試驗。將與左旋氟羅沙辛1〇〇毫克相當量之 散劑實際含於口中,以評價味道及服用感。確認各種散劑 所持有之極強不快味被遮蔽3〇秒以上。再者,服用後經 過10秒鐘時間,口中沒有異物感之感覺。 (不快味道之遮蔽性之評價:溶出試驗1) 用實例1彳寸到之散劑940毫克及實例2得到之散劑950 見克進行不快味遒遮蔽試驗。不快味道遮蔽試驗係使用溶 出試驗裝置,試驗液使用精製水500毫升,試驗液溫度爲 37 °C,以槳攪法於迴轉數爲1〇〇 rpm之條件下進行。使用 未加包衣之藥物做爲對照組。結果(溶出率(%))如表工所 示。藥物從散劑巾之初期溶出,與未加包衣藥物者相較, 顯示被顯著之抑制。 表1 溶出試驗結果 時間(秒) 10 20 30 60 未加包衣藥物 58 83 93 ----— 103 實例1 2 6 12 ——-— 29 實例2 5 12 19 40 經濟部智慧財產局員工消費合作社印製 試驗例3(經插管投與之適用性之評價1 ) 評價實例1與實例2得到之散劑在經插營 &仅與方面之 用性。分別將950亳克分散於20毫升精製水中。夕 、 液移入用完即丟棄之注射器中,接上經將此+散 @蚕補給用管 ____-22- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公羞) A7 B7
1251495 五、發明說明(20 ) (日本舍伍德公司製[阿蓋爾型]新腸内輸入管,内徑ι〇亳 米)。將分散液彳疋注射备擠出’評價注射器前端及管子前 端之堵塞情形。其結果如表2所示。 表2 __經插管投與之適用性之評價結果 結果 實例1 確認注射器前端及管子前端完全沒有堵宸。 實例2 確認注射器前端及管子前端完全沒有堵塞^ 實例1及實例2得到之散劑未造成堵塞,因此確認可順 利投與。 試驗例4 (溶出試驗1 ) 用實例1得到之散劑940毫克及實例2得到之散劑95〇 毫克進行溶出試驗。溶出試驗係使用溶出試驗裝置,試驗 液係使用日本藥局方第13次修訂版記載之崩散試驗第i 液900毫升,試驗液溫度爲37 X:,以槳攪法於迴轉數爲5〇 rpm進行試驗。其結果如表3所示,確認此等散劑顯示良 好之溶出性。 -23- 本紙張尺錢财目國家標準(CNS)A4規格(210 X 297公釐) -!-11——0--------訂---------線_ (請先閱讀背面之注咅?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1251495 A7 B7 五、發明說明(21 ) 表 溶出試驗結果 溶出率(%)) 時間 實例1 實例2 5分後 10分後 20分後 3〇分後 45分後 60分後 100 100 100 100 100 100 98 98 98 98 98 98 經 濟 部 智 慧 財 產 局 員 工 消 費 合 作 社 印 製 實例3 使三脂肪酸甘油醋216重量份在約80 °C溶解,在其中將 11.2重量份之聚山梨酸酯80混合。然後將氯皮都克莱爾 (chlopidogrel)硫酸鹽97.8重量份均勻分散於此混合液中。 將此分散液用噴霧乾燥器噴霧冷卻,得到微小造粒物。在 此造粒物325重量份中添加原藻醇ι69重量份及阿斯巴甜 5重量份並加以混合,得到散劑。 實例4 使二脂肪酸甘油酯216重量份在約80 °C熔解,在其中混 合入1.2重量份之聚山梨酸酯8〇 ^然後將氯皮都克萊爾 (chlopuiogrel)硫酸鹽97.8重量份均勻分散於此混合液中。 將此分散液用噴霧乾燥器噴霧冷卻,得到微小造粒物。在 此造粒物325重量份中加入原藻醇169重量份,使用流動 層造粒機混合後,以相當於聚乙烯醇20重量份之10W/V% 聚乙缔醇水溶液喷霧,進行流動造粒。噴霧終了後,繼續 在流動層造粒機内進行乾燥,得到造粒物。將此造粒物 514重量份與阿斯巴甜5重#份混合,得到散劑。
x 297公釐) (請先閱讀背面之注音?事項再填寫本頁) 0 訂---------線· A7
1251495 五、發明說明(22 ) 實例5 使三脂肪酸甘油酯216重量份溶解在二氯甲跪中。然後 將氯皮都克萊爾(chlopidogrel)硫酸鹽97.8重量份與乙基纖 維素32.6重量份均勻分散於此液中。將此分散液用噴霧乾 燥器噴霧冷卻,得到微小造粒物。在此造粒物346.4重量 份中添加原藻醇147.6重量份及阿斯巴甜5重量份,得到 散劑。 實例6 使三脂肪酸甘油酯216重量份溶解於二氯甲烷中。然 後’將氯皮都克莱爾(chlopidogrel)硫酸鹽97.8重量份與乙 基纖維素32.6重量份均勻分散於此液中。將此分散液用噴 務乾故器噴霧冷卻,得到微小造粒物。在此造粒物346 4 重里份中添加原藻醇147.6重量份,使用流動層造粒機混 合後,以相當於聚乙烯醇20重量份之1〇w/V%聚乙烯醇水 溶液噴霧,進行流動造粒。噴霧終了後,繼續在流動層造 粒機内進行乾燥,得到造粒物。將此造粒物514重量份與 阿斯巴甜5重量份混合,得到散劑。 對照例1 使三脂肪酸甘油酯135重量份在約8〇熔解,在其中混 合入7重量份之聚山梨酸酯8〇。然後將氯皮都克莱爾 (chlopidogrel)硫酸鹽61重量份均勻分散於此混合液中。將 此分散液用噴霧乾燥器噴霧冷卻,得到微小造粒物。在此 造粒物346.4重量份中添加乳糖147·6重量份及阿斯巴甜5 重量份並加以混合,得到散劑。 ______-25- 本紙張尺度適用中國國家標準(CNS)A4X格(210 X 297公爱) ----ill· — — ——#--------訂---------線· {請先閱讀背面之注音?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1251495 經 濟 部 智 慧 財 產 局 員 工 消 費 合 作 社 印 製 A7 B7
1251495 A7 五、發明說明(24 表4 與之適用性之許價結果 ~__ 結果 對照例1 剛擠出後,管子前端有製劑堵塞,使得分散 擠出。 實例5 器前端及管子前端完全沒有堵 經濟部智慧財產局員工消費合作社印製 對肤例1得到之散劑投與困難,無法確認適合經Η挪卞 投與。與此相對地,實例5得到之散劑未造成堵塞,確認 可順利投與。 夂 爸㉟例8(溶出試驗2 ) 用貝例3知到之散劑326·5毫克進行溶出試驗。溶出試 驗係使用溶出試驗裝置,試驗液係使用日本藥局方第= 次修訂版記載之崩散試驗第】液900毫升且其中添加有1% 十二垸基㈣n驗液溫度爲37τ ’以槳授法於迴轉 數爲50 rpm之條件下進行試驗。其結果如表5所示,確認 實例3顯示良好之溶出性。 表5 由插管 溶出試驗結果
.27- &紙張尺度適用尹國國家標準(CNS)A4規格⑵G X 297公I" ——rill· — ———0--------訂---------線余 (請先閱讀背面之注意事項再填寫本頁) 1251495 A7 B7 五、發明說明(25 ) 產業上利用之可能性 若依照本發明,可得到藥物之不快味道之遮蔽性優異, 服用感良好,對於高齡者、小孩及吞嚥困難之患者,也能 很容易地服用之醫藥製劑。此製劑也適合經插管投與。 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 -28- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1251495 > ;; V: 申請曰期 ;、/7) 案 號 089104960 類 別 以上各欄由本局填註) A4 C4 中文說明書替換頁(95年元月) 發明 新型 名稱 中 英 文 文 姓 名 國 籍 無不快味道之醫藥組合物 "PHARMACEUTICAL COMPOSITON WITHOUT UNPLEASANT TASTE,,_ 1. 中上博秋 2. 餘木達也 3. 小林英夫 4. 黑澤晃 發明 創作 人 均曰本 住、居所 均日本國東京都江戶川區北葛西1-16-13 曰商第一製藥股份有限公司東京研究開發中心内 裝 姓 名 (名稱) 國 籍 三、申請人 住、居所 (事務所) 代表人 姓 名 曰商第一製藥股份有限公司 曰本 曰本國東京都中央區日本橋3丁目14番10號 森田清 線 本紙張尺度適用中國國家標準(CNS) A4規格(210X297公釐)
Claims (1)
1251你(59104960號專利申請案 A8 中文申請專利範圍替換本(94年I2月)g D8 六、申請專利範圍 1· 一種粒狀醫藥組合物,其含有粒狀物與糖醇,該粒狀 物含有粒徑為5 0〜2 Ο Ο μ m之呈現不快味道之藥物及 蠟狀物質,其中該蠟狀物質係由硬化油、植物性或動 物性油脂、高級醇、聚乙二醇、高級脂肪酸、甘油之 脂肪酸酯類及蔗糖之脂肪酸酯類中選出之1種或2種 以上之蠟狀物質,該糖醇係由原藻醇、木糖醇、山梨 糖醇及麥芽糖醇中選出之1種或2種以上之糖醇,該 呈現不快味道之藥物係選自下列藥物:嘧德拉赛特 (cetraxate)鹽酸鹽、埃卡巴皮多、涅飛拉血丹、酞胺苄 青黴素(talanpicillin)鹽酸鹽、印得諾樂爾(indenolol)鹽酸 鹽、肼酉太唤(hydralazine)鹽酸鹽、氯丙嗪(chl〇rpromazine) 鹽酸鹽、續胺遠唑(thiazamide)鹽酸鹽、氯化小蘗鹼 (berberine chloride)、毛地黃毒苷(digitoxin)、安乃近 (sulpyrin)、阿瑟拉斯汀鹽酸鹽、乙苯福林(etiiefrine)鹽 酸鹽、硫氮萆酮(diltiazem)鹽酸鹽、莕心安(pr〇pran〇i〇i) 鹽酸鹽、氯黴素(chloramphenicol)、胺基菲林 (aminophyllin)、紅黴素、澄清黴素(clarithromycin)、苯 巴比妥(phenobarbital)、泛酸鈣、印得羅莎淀鹽酸鹽、 胺基胍(aminoguanidine)鹽酸鹽、比菲美藍鹽酸鹽、7β-[2- ( 2-胺基嘧唑—4-基)-2-(Ζ)-羥亞胺基乙醯胺]-3-Ν,Ν-二 甲胺曱酸氧甲基-3-瑟菲姆(cephem)幾酸1-(異丙氧羰氧 基)乙酯鹽酸鹽、(E)-3-(2-甲氧基-3,6-二甲基-1,4·苯醌- 本紙張尺度適用中國國家標準(CNS) Α4規格(210 X 297公釐) 1251495 as B8 C8 D8 穴、申請專利範圍 5-基)-2- [5-(3- p比淀基)戊基]-2-丙婦酸、胺基菲林 (aminophyllin)、茶驗(theophylline)、苯海拉明 (diphenhydramine)、滅吐靈(metoclopramide)、苯基保泰松 (phenylbutazone)、苯巴比妥(phenobarbital)、胺爷青黴素 (ampicillin)、西美替淀(cimetidine)、法摩替淀 (famotidine)、尼札替淀(nizatidine)、乙酿胺基苯酴 (acetoaminophen)、野匹立柔(epirizol) 、p比嗪酸胺 (pyrazinamide)、咖啡因、乙硫異煙胺(ethionamide)、卡 威迪柔(carvedilol)、糖硝埽二胺(^11如(1丨1^)鹽酸鹽、乙 酸羅沙淀酿(roxatidine acetate)鹽酸鹽、丙咪嗪 (imipramine)鹽酸鹽、麻黃驗(ephedrine)鹽酸鹽、苯海拉 明(diphenhydramine)鹽酸鹽、斗内戊基鹽酸鹽、四環素 鹽酸鹽、去氧土黴素(doxycycline)鹽酸鹽、莕吐淋 (naphazoline)鹽酸鹽、諾司卡品(noscapine)鹽酸鹽、畧粟 鹼 (papaverine) 鹽酸鹽、氫溴酸美沙芬 (dextromethorphan)、溴化嘍甲吡啶(timepidium bromide)、 馬來酸氯苯ρ比胺(chlorpheniramine maleate)、酒石酸阿立 眉馬啶、皮爾丁卡耐德鹽酸鹽、N-甲基莨菪胺 (scopolamine)甲基硫酸鹽、馬來酸西涅帕紀德、精胺酸 鹽酸鹽、組胺酸鹽酸鹽、離胺酸鹽酸鹽、離胺酸醋酸 鹽、恩格沙克、黃柏、黃蓮、馬錢子、麻黃、吐根、 藍奮根、顛蘇、苦參等之生藥或者此等生藥之萃取 -2- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐) 8 8 8 8 A BCD 1251495 六、申請專利範園 物、以下述通式(1)〜(4)所表示之吡啶酮羧酸化合物或其 鹽類:
R2a 〇 :軟H R4a Rla (1 ) R25 Ο ,χχι Rib * (3·) (式中= Rla、Rlb及Rle分別獨立表示可具有取代基之CrC6直 鏈狀或分枝狀烷基、可具有取代基之C3-C6之環烷基、 可具有取代基之芳基或可具有取代基之雜芳基; R2a、R2b、R2e及R2d分別獨立表示氫原子、可具有取 代基之CkC6直鏈狀或分枝狀虎基、或胺基; R3a、R3b、R3e及R3d分別獨立表示氫原子或鹵素原 子; R4a或R4e表示氫原子、鹵素原子、可具有取代基之 Ci-C6直鏈狀或分枝狀烷基或可具有取代基之Cl-C6直鏈 -3 - 本紙張尺度適用中國國家標準(CNS) A4規格(21〇 χ 297公釐) 1251495 as B8 C8 D8 六、申請專利範圍 狀或分枝狀烷氧基; R5d表示氫原子或可具有取代基之Ci-C6直鏈狀或分枝 狀烷基;以及 Ya、Yb、Ye及Yd分別獨立表示含氮基),且 該呈現不快味道之藥物與蠟狀物質之配合重量比為 1:1〜1:5,糖醇之含量為組合物之10%重量以上。 2·根據申請專利範圍第1項之粒狀醫藥組合物,其中該糖 醇係原藻醇及/或木糖醇。 3·根據申請專利範圍第1項之粒狀醫藥組合物,其中該呈 現不快味道之藥物係歐氟羅沙辛(ofloxacin)。 4·根據申請專利範圍第1項之粒狀醫藥組合物,其中該呈 現不快味道之藥物係左旋氟羅沙辛(lev〇fl〇xacin)。 5·根據申請專利範圍第1項之粒狀醫藥組合物,其中該呈 現不快味道之藥物係氯皮都克莱爾(chl〇pid〇grel)硫酸 鹽。 6·根據申請專利範圍第丨項之粒狀醫藥組合物,係藉由將 蠟狀物質加溫熔解並將呈現不快味道之藥物分散或溶 解於其中後,用該液進行第一次造粒,然後將得到之 U粒物與糖醇進行混合或第二次造粒而得到。 7. 根據申請專利範圍第丨項之粒狀醫藥組合物,其中該第 一次造粒為噴霧造粒。 8. 一種"服醫藥製劑,其含有中請專利範圍f i〜7项中任 -4-
1251495 A8 B8 C8 D8 、申請專利範圍 一項之粒狀醫藥組合物。 9. 根據申請專利範圍第8項之口服醫藥製劑,其劑型為散 劑或顆粒劑。 10. —種粒狀醫藥組合物之製法,其係用於製造根據申請 專利範圍第1項之粒狀醫藥組合物者,且係將蠟狀物 質加溫熔解並將呈現不快味道之藥物分散或溶解於其 中後,用該液進行第一次造粒,然後將得到之粒徑為 50〜2 0 0 μιη之造粒物與糖醇進行混合或第二次造粒 者0 -5- 本紙張尺度適用中國國家標準(CNS) Α4規格(210X297公釐)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP7214599 | 1999-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI251495B true TWI251495B (en) | 2006-03-21 |
Family
ID=13480822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW089104960A TWI251495B (en) | 1999-03-17 | 2000-03-17 | Pharmaceutical composition without unpleasant taste |
Country Status (12)
Country | Link |
---|---|
US (3) | US20050152975A1 (zh) |
EP (2) | EP2275141A1 (zh) |
JP (2) | JP4694669B2 (zh) |
KR (1) | KR100768034B1 (zh) |
CN (1) | CN1343128B (zh) |
AU (1) | AU3192700A (zh) |
CA (1) | CA2367373C (zh) |
HK (1) | HK1044476B (zh) |
NO (1) | NO20014490L (zh) |
RU (1) | RU2270695C2 (zh) |
TW (1) | TWI251495B (zh) |
WO (1) | WO2000054811A1 (zh) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4570725B2 (ja) * | 2000-04-05 | 2010-10-27 | 大塚製薬株式会社 | 医薬製剤用組成物 |
US20040022848A1 (en) * | 2000-09-19 | 2004-02-05 | Hiroshi Kikuchi | Medicinal composition |
WO2002038577A2 (en) * | 2000-10-13 | 2002-05-16 | Advancis Pharmaceuticals | Extended release erythromycin derivatives |
JP2002138034A (ja) * | 2000-10-27 | 2002-05-14 | Kyoto Pharmaceutical Industries Ltd | 苦味マスキングチュアブル錠およびその製造方法 |
BR0207930A (pt) | 2001-03-05 | 2004-03-02 | Ortho Mcneil Pharm Inc | Composições farmacêuticas lìquidas com sabor mascarado |
US20040146553A1 (en) | 2002-12-23 | 2004-07-29 | Aventis Pharma S.A. | Compositions for oral administration of active principles requiring masking of taste |
FR2848855B1 (fr) * | 2002-12-23 | 2005-02-11 | Aventis Pharma Sa | Compositions pour administration orale de principes actifs necessitant un masquage du gout |
DE10305984A1 (de) * | 2003-02-13 | 2004-09-02 | Helm Ag | Salze organischer Säuren mit Clopidogrel und deren Verwendung zur Herstellung phamazeutischer Formulierungen |
WO2004087096A1 (en) * | 2003-04-02 | 2004-10-14 | Pliva-Istrazivanje I Razvoj D.O.O. | Pharmaceutical compositions having reduced bitter taste |
DK1669090T3 (en) * | 2003-09-12 | 2016-06-06 | Ryukakusan Co Ltd | Bitterness masking particulate gel |
JP4385802B2 (ja) * | 2004-03-16 | 2009-12-16 | 味の素株式会社 | 粉末透析剤の製造方法 |
ES2704482T3 (es) | 2004-11-24 | 2019-03-18 | Meda Pharmaceuticals Inc | Composiciones que comprenden azelastina y sus métodos de uso |
US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
US9101160B2 (en) | 2005-11-23 | 2015-08-11 | The Coca-Cola Company | Condiments with high-potency sweetener |
EP2001445B1 (en) * | 2006-03-16 | 2014-07-23 | Euro-Celtique S.A. | Pharmaceutical spheroids |
WO2008001201A2 (en) * | 2006-06-28 | 2008-01-03 | Wockhardt Ltd | Pharmaceutical compositions of clopidogrel |
EP1900358A1 (en) * | 2006-09-16 | 2008-03-19 | Cimex Pharma AG | Pharmaceutical formulations comprising clopidogrel |
US8017168B2 (en) | 2006-11-02 | 2011-09-13 | The Coca-Cola Company | High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith |
JP5318400B2 (ja) * | 2006-11-20 | 2013-10-16 | 第一三共株式会社 | レボフロキサシン含有錠剤 |
US20090028935A1 (en) * | 2006-12-01 | 2009-01-29 | Kristin Arnold | Carvedilol forms, compositions, and methods of preparation thereof |
WO2008070072A2 (en) * | 2006-12-01 | 2008-06-12 | Mutual Pharmaceutical Company, Inc. | Carvedilol forms, compositions, and methods of preparation thereof |
FR2913884A1 (fr) * | 2007-03-21 | 2008-09-26 | Oralance Pharma Sa | Systeme galenique hydrophobe non ionisable |
ES2376057T3 (es) * | 2008-02-26 | 2012-03-08 | Laboratorios Lesvi, S.L. | Formulaciones farmacéuticas que contienen clopidogrel. |
EP2198859A1 (en) * | 2008-12-17 | 2010-06-23 | Losan Pharma GmbH | Melt-coated pharmaceutical composition with fast release |
US20110021591A1 (en) | 2009-07-21 | 2011-01-27 | Gordon Douglas J | Phenylbutazone carrier formulation showing increased bioactivity in animals |
JP2013032289A (ja) * | 2009-10-28 | 2013-02-14 | Daiichi Sankyo Co Ltd | ワックス安定製剤 |
JP5725884B2 (ja) * | 2011-01-27 | 2015-05-27 | 理研ビタミン株式会社 | 経口用製剤 |
US9119793B1 (en) | 2011-06-28 | 2015-09-01 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for doxycycline |
CN103181885A (zh) * | 2011-12-30 | 2013-07-03 | 北京韩美药品有限公司 | 氯吡格雷的固体制剂及制备方法 |
US10842802B2 (en) | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
HUP1400294A2 (hu) | 2014-06-13 | 2015-12-28 | Skillpharm Kft | Clopidogrel új alkalmazása |
CN107335058B (zh) * | 2017-07-31 | 2021-01-08 | 暨南大学 | 一种2,6-二取代吡啶-4-硫代甲酰胺的新用途 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2215948B1 (zh) | 1973-02-01 | 1976-05-14 | Centre Etd Ind Pharma | |
JPS53141286A (en) | 1977-05-16 | 1978-12-08 | Kyorin Seiyaku Kk | Novel substituted quinolinecarboxylic acid |
JPS5531042A (en) | 1978-08-25 | 1980-03-05 | Dainippon Pharmaceut Co Ltd | 1,8-naphthylidine derivative and its salt |
JPS5746986A (en) | 1980-09-02 | 1982-03-17 | Dai Ichi Seiyaku Co Ltd | Pyrido(1,2,3-de)(1,4)benzoxazine derivative |
DE3033157A1 (de) | 1980-09-03 | 1982-04-01 | Bayer Ag, 5090 Leverkusen | 7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-naphthyridin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel |
FR2508459A1 (fr) | 1981-06-30 | 1982-12-31 | Sanofi Sa | Procede de preparation de derives de la tetrahydro-5,6,7,7a 4h thieno (3,2-c) pyridinone-2 |
FR2530247B1 (fr) | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
FR2548664B1 (fr) | 1983-07-06 | 1986-03-21 | Provesan Sa | Derives 7-(pyrrol-l-yl) des acides l-ethyl-1,4-dihydro-4-oxoquinoleine-3-carboxyliques et l-ethyl-1,4-dihydro-4-oxo-(1,8-naphtyridine)-3-carboxyliques substitues, leur preparation et leur application en tant que medicaments |
JPS6064979A (ja) | 1983-09-19 | 1985-04-13 | Hokuriku Seiyaku Co Ltd | 7−ピペラジン置換−6−フルオロ−4−オキソ−1,4−ジヒドロキノリン−3−カルボン酸誘導体 |
JPS60228479A (ja) | 1984-04-26 | 1985-11-13 | Toyama Chem Co Ltd | 1,4−ジヒドロ−4−オキソナフチリジン誘導体およびその塩 |
ZA864518B (en) | 1985-06-20 | 1987-03-25 | Daiichi Seiyaku Co | Optically active pyridobenzoxazine derivatives and intermediates thereof |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
AU594983B2 (en) | 1985-10-29 | 1990-03-22 | Dainippon Pharmaceutical Co. Ltd. | Novel quinoline derivatives and processes for preparation thereof |
JPH089597B2 (ja) | 1986-01-21 | 1996-01-31 | 杏林製薬株式会社 | 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法 |
US5591744A (en) | 1987-04-16 | 1997-01-07 | Otsuka Pharmaceutical Company, Limited | Benzoheterocyclic compounds |
NL193682C (nl) * | 1987-05-14 | 2000-07-04 | Glaxo Group Ltd | Beklede cefuroximaxetilsamenstelling. |
JPH0751579B2 (ja) | 1987-11-07 | 1995-06-05 | 日本新薬株式会社 | キノリンカルボン酸誘導体 |
JPH0228178A (ja) | 1988-04-23 | 1990-01-30 | Toyama Chem Co Ltd | 新規なピリドンカルボン酸誘導体およびその塩並びにそれらの製造法 |
MY105136A (en) | 1988-04-27 | 1994-08-30 | Daiichi Seiyaku Co | Optically active pyridonecarboxylic acid derivatives. |
JPH0645601B2 (ja) | 1988-07-20 | 1994-06-15 | 三共株式会社 | キノロンカルボン酸誘導体 |
JPH01258666A (ja) | 1988-08-18 | 1989-10-16 | Kyorin Pharmaceut Co Ltd | 新規置換キノリンカルボン酸 |
WO1991002526A1 (en) | 1989-08-16 | 1991-03-07 | Pfizer Inc. | Azabicyclo quinolone carboxylic acids |
US5320848A (en) * | 1991-05-28 | 1994-06-14 | Affinity Biotech, Inc. | Chewable drug-delivery composition |
FI101150B (fi) | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
TW209865B (zh) | 1992-01-10 | 1993-07-21 | Bayer Ag | |
KR100218700B1 (ko) * | 1992-03-12 | 1999-09-01 | 우에하라 아끼라 | 경구용조성물 |
JP3265680B2 (ja) * | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
KR950703935A (ko) * | 1992-11-30 | 1995-11-17 | 밋첼 아이, 커시너 | 맛을 차단하는 약제학적 조성물 |
WO1994014794A1 (en) | 1992-12-28 | 1994-07-07 | Yoshitomi Pharmaceutical Industries, Ltd. | 8-methoxyquinolonecarboxylic acid derivative |
US5527910A (en) | 1992-12-30 | 1996-06-18 | Cheil Foods & Chemicals, Inc. | Pyridone carboxylic acid compounds and their uses for treating infectious diseases caused by bacteria |
WO1995005373A1 (en) | 1993-08-13 | 1995-02-23 | Dong Wha Pharmaceutical Industrial Co., Ltd. | Novel quinolone carboxylic acid derivatives |
TW252107B (zh) | 1993-08-27 | 1995-07-21 | Hokuriku Pharmacetical Co Ltd | |
JPH07242568A (ja) | 1994-03-04 | 1995-09-19 | Eisai Co Ltd | 苦味隠蔽製剤 |
JPH07267850A (ja) | 1994-03-28 | 1995-10-17 | Eisai Co Ltd | 不快味を防止した医薬組成物及びその製造方法 |
JPH07285838A (ja) * | 1994-04-15 | 1995-10-31 | Lion Corp | 口腔用組成物 |
EP0688772B1 (en) | 1994-06-16 | 1999-05-06 | LG Chemical Limited | Quinoline carboxylic acid derivatives having 7-(4-amino-methyl-3-oxime) pyrrolidine substituents and processes for their preparation |
US5972373A (en) * | 1995-05-02 | 1999-10-26 | Taisho Pharmaceutical Co., Ltd. | Taste masking pharmaceutical composition for oral administration |
US5602254A (en) | 1995-05-26 | 1997-02-11 | Warner-Lambert Company | Method for making quinoline carboxylic acids or naphthyridine carboxylic acids in free base form |
JPH11510478A (ja) | 1995-06-06 | 1999-09-14 | アボツト・ラボラトリーズ | キノリジノン型化合物 |
ATE283038T1 (de) * | 1995-07-21 | 2004-12-15 | Daiichi Seiyaku Co | Verfahren zu herstellung einer granulären zubereitung |
IT1276160B1 (it) * | 1995-11-22 | 1997-10-27 | Recordati Chem Pharm | Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee |
NZ322202A (en) | 1995-11-22 | 2000-05-26 | Daiichi Pharmaceutical Company | Aminocycloalkylpyrrolidine derivatives and salts thereof with antibacterial activity |
CA2242242C (en) | 1996-02-09 | 2001-08-07 | Toyama Chemical Co., Ltd. | Quinolonecarboxylic acid derivatives or salts thereof |
ID16655A (id) | 1996-04-24 | 1997-10-30 | Daiichi Seiyaku Co | Turunan-turunan sikloalkilaminometilpirolidina |
PT919553E (pt) | 1996-07-12 | 2005-05-31 | Daiichi Seiyaku Co | Derivados de aminociclopropano cis-substituidos |
TW519542B (en) | 1996-09-27 | 2003-02-01 | Daiichi Seiyaku Co | Bicyclic amine derivative |
ES2221040T3 (es) | 1996-10-25 | 2004-12-16 | Daiichi Pharmaceutical Co., Ltd. | Derivados de amina triciclicos. |
AU1040597A (en) | 1996-12-04 | 1998-06-29 | Daiichi Pharmaceutical Co., Ltd. | Substituted aminomethylpyrrolidine derivatives |
WO1998052939A1 (fr) | 1997-05-21 | 1998-11-26 | Daiichi Pharmaceutical Co., Ltd. | Derives d'aminocycloalkyle-pyrrolidine cis-disubstitues |
ZA984527B (en) | 1997-05-30 | 1998-12-03 | Daiichi Seiyaku Co | Substituted cyclobutylamine derivative |
AU8038798A (en) | 1997-06-24 | 1999-01-04 | Daiichi Pharmaceutical Co., Ltd. | Cis-substituted fluoromethylpyrrolidine derivatives |
JPH1135486A (ja) * | 1997-07-23 | 1999-02-09 | Lion Corp | 薬用固形製剤 |
US6432442B1 (en) * | 1998-02-23 | 2002-08-13 | Mcneil-Ppc, Inc. | Chewable product |
-
2000
- 2000-03-16 EP EP10010622A patent/EP2275141A1/en not_active Withdrawn
- 2000-03-16 KR KR1020017011627A patent/KR100768034B1/ko not_active IP Right Cessation
- 2000-03-16 CN CN008050538A patent/CN1343128B/zh not_active Expired - Fee Related
- 2000-03-16 CA CA2367373A patent/CA2367373C/en not_active Expired - Fee Related
- 2000-03-16 AU AU31927/00A patent/AU3192700A/en not_active Abandoned
- 2000-03-16 RU RU2001128071/15A patent/RU2270695C2/ru not_active IP Right Cessation
- 2000-03-16 JP JP2000073572A patent/JP4694669B2/ja not_active Expired - Lifetime
- 2000-03-16 EP EP00909677A patent/EP1161956A4/en not_active Withdrawn
- 2000-03-16 WO PCT/JP2000/001606 patent/WO2000054811A1/ja not_active Application Discontinuation
- 2000-03-17 TW TW089104960A patent/TWI251495B/zh not_active IP Right Cessation
-
2001
- 2001-09-14 NO NO20014490A patent/NO20014490L/no not_active Application Discontinuation
-
2002
- 2002-08-22 HK HK02106154.7A patent/HK1044476B/zh not_active IP Right Cessation
-
2004
- 2004-10-07 US US10/959,297 patent/US20050152975A1/en not_active Abandoned
-
2006
- 2006-12-01 US US11/565,733 patent/US20070148235A1/en not_active Abandoned
-
2010
- 2010-10-08 JP JP2010228566A patent/JP2011006481A/ja active Pending
-
2011
- 2011-01-06 US US12/985,476 patent/US20110159049A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NO20014490L (no) | 2001-11-14 |
EP1161956A4 (en) | 2005-03-16 |
JP2000327590A (ja) | 2000-11-28 |
EP2275141A1 (en) | 2011-01-19 |
CA2367373A1 (en) | 2000-09-21 |
NO20014490D0 (no) | 2001-09-14 |
HK1044476B (zh) | 2010-09-17 |
WO2000054811A1 (fr) | 2000-09-21 |
CN1343128B (zh) | 2010-04-21 |
US20110159049A1 (en) | 2011-06-30 |
CN1343128A (zh) | 2002-04-03 |
AU3192700A (en) | 2000-10-04 |
CA2367373C (en) | 2011-09-20 |
US20070148235A1 (en) | 2007-06-28 |
US20050152975A1 (en) | 2005-07-14 |
JP2011006481A (ja) | 2011-01-13 |
HK1044476A1 (en) | 2002-10-25 |
RU2270695C2 (ru) | 2006-02-27 |
JP4694669B2 (ja) | 2011-06-08 |
KR20010102571A (ko) | 2001-11-15 |
KR100768034B1 (ko) | 2007-10-17 |
EP1161956A1 (en) | 2001-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI251495B (en) | Pharmaceutical composition without unpleasant taste | |
US8647668B2 (en) | Tablet quickly disintegrating in oral cavity | |
EP1523974B1 (en) | Composition for rapid disintegrating tablet in oral cavity | |
JP5637624B2 (ja) | 崩壊性粒子組成物及びそれを用いた速崩壊性圧縮成型物 | |
KR101551506B1 (ko) | 레바미피드를 함유하는 의약 조성물 | |
JP2014132022A (ja) | 医薬組成物 | |
JPWO2009157214A1 (ja) | 球状非結晶ケイ酸アルミン酸マグネシウム | |
WO2016051782A1 (ja) | 苦味を有する薬剤の苦味をマスキングした経口投与製剤 | |
EP2308464A1 (en) | Orally disintegrating compositions of pramipexole | |
JP4691925B2 (ja) | 圧縮成型製剤の製造方法 | |
BR112018074434B1 (pt) | Pluralidade de partículas compreendendo safinamida, processo para a preparação das mesmas e comprimido de desintegração oral | |
KR102090135B1 (ko) | 솔리페나신 또는 이의 약제학적으로 허용가능한 염을 포함하는 구강 붕해정 및 이의 제조방법 | |
JP2011046750A (ja) | 口腔内速崩壊性錠 | |
JP7148319B2 (ja) | プラスグレルを含む口腔内崩壊錠 | |
ES2915026T3 (es) | Composiciones farmacéuticas que comprenden safinamida | |
JP2021001122A (ja) | 不快な官能的性質をもつ薬剤をマスキングした医薬固形製剤 | |
CN115803020A (zh) | 含有苯磺酸米洛巴林的口腔崩解片剂 | |
JP2018044017A (ja) | 粒子製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |